Broker\'s call: GlaxoSmithKline Pharmaceuticals

Stocks

Broker's call: GlaxoSmithKline Pharmaceuticals

| Updated on May 26, 2020 Published on May 27, 2020

Centrum Broking

GlaxoSmithKline Pharmaceuticals (Add)

CMP: ₹1,370.5

Target: ₹1,570

GSK Pharmaceutical’s Q4FY20 reported earnings ahead of our estimates. The earnings were better as gross margins continued to improve significantly, this quarter gross margins stood at 64 per cent versus 54.4 per cent vs 57.9 per cent. The improvement was largely attributable to price mix and portfolio optimisation. Accordingly we believe that both these elements could be sustainable over the coming years and could mean better gross margins.

The employee cost also increased by 17 per cent y-o-y and has certain element of one-time. EBITDA increased by 6 per cent y-o-y to ₹174 crore with EBITDA margins at 22.4 per cent, expanded by 60 bps y-o-y. Reported profit for the quarter was at ₹129 crore, increased 6.7 per cent y-o-y. The underlying sales growth adjusting for tail-end brand rationalisation and divestment was at 13 per cent y-o-y while the key focussed brands growth stood at 20 per cent y-o-y (both for vaccines and other focussed brands). Top brands continue to grow at +20 per cent.

Management maintains their guidance on sustaining double digit underlying growth and expects EBITDA margins to reach around 23-25 per cent going ahead.

Published on May 27, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
BSE launches eKYC services on StAR MF platform